SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMC NEWS

TMCNET eNEWSLETTER SIGNUP

Athenex to Present at the 2019 ASCO Annual Meeting
[May 30, 2019]

Athenex to Present at the 2019 ASCO Annual Meeting


BUFFALO, N.Y., May 30, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will present data and exhibit at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 to June 4, 2019, at the McCormick Place Convention Center in Chicago, Illinois.

Athenex will introduce its new brand established for the oncology platform, Athenex Oncology, at its exhibition booth (#4150) at ASCO 2019 (exhibition dates: June 1 to 3, 2019), which will also showcase the potential of the Orascovery Platform and latest development pipeline.

Athenex has four abstracts accepted for poster presentation and two abstracts accepted for online publication only.

Details of Poster Presentations:

Title: (Abstract TPS1116) KX-ORAX-001: An open label, randomized, multicenter, Phase III registrational study to determine the safety, tolerability, and tumor response of Oraxol (HM30181A + oral paclitaxel) and its comparability to IV paclitaxel in patients with metastatic breast cancer (MBC).
Presenter: Gerardo Antonio Umanzor Funez, DEMEDICA, San Pedro Sula, Honduras
Poster Session: Breast Cancer—Metastatic
Session Date, Time, Location: Sunday, June 2, 2019, 8:00 AM-11:00 AM Central Daylight Time, Hall A
The abstract is available on the ASCO website here.

Title: (Abstract 1084) Oral paclitaxel in the treatment of metastatic breast cancer (MBC) patients.
Presenter: Ming-Shen Dai, Tri-Service General Hospital, Taipei, Taiwan
Poster Session: Breast Cancer—Metastatic
Session Date, Time, Location: Sunday, June 2, 2019, 8:00 AM-11:00 AM Central Daylight Time, Hall A
The abstract is available on the ASCO website here.

Title: (Abstract 3032) A Phase 1 study of the oral administration of irinotecan in combination with the potent P-glycoprotein (P-gp) inhibitor HM30181A.
Presenter: Antonio Jimeno, University of Colorado, Aurora, CO
Poster Session: Develomental Therapeutics and Tumor Biology (Nonimmuno)



Session Date, Time, Location: Saturday, June 1, 2019, 8:00 AM-11:00 AM Central Daylight Time, Hall A
The abstract is available on the ASCO website here.

Title: (Abstract 3090) Design, engineering, and characterization of a novel long-acting (Pegylated) single isomer human arginase for arginine depriving anti-cancer treatment.
Presenter: Kuo-Ming Yu, Athenex, Inc., Buffalo, NY
Poster Session: Developmental Therapeutics and Tumor Biology (Nonimmuno)
Session Date, Time, Location: Saturday, June 1, 2019, 8:00 AM-11:00 AM Central Daylight Time, Hall A
The abstract is available on the ASCO website here.


Abstracts Accepted for Online Publication Only:

Title: (Abstract e15518) A phase Ib study of oraxol in combination with ramucirumab in patients with gastric or esophageal cancers who failed previous chemotherapy.
The abstract is available on the ASCO website here.

Title: (Abstract e12577) Eribulin ORA: A novel oral formulation of eribulin based on combination with
the P-gp inhibitor HM30181A.
The abstract is available on the ASCO website here.

The Orascovery platform was initially developed by Hanmi Pharmaceuticals and licensed exclusively to Athenex for all major worldwide territories except Korea, which is retained by Hanmi.

About Athenex, Inc.
Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery, development and commercialization of next generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform and a Global Supply Chain Platform. The Company’s current clinical pipeline is derived from four different platform technologies: (1) Orascovery, based on non-absorbed P-glycoprotein inhibitor, (2) Src kinase inhibition, (3) T-cell receptor-engineered T-cells (TCR-T), and (4) Arginine deprivation therapy. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments.  Athenex has offices in Buffalo and Clarence, New York; Cranford, New Jersey; Houston, Texas; Chicago, Illinois; Hong Kong; Taipei, Taiwan; and multiple locations in Chongqing, China. For more information, please visit www.athenex.com.

Forward-Looking Statements
Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. These forward-looking statements are typically identified by terms such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “foresee,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions.  Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the development stage of our primary clinical candidates and related risks involved in drug development, clinical trials, regulation, manufacturing and commercialization; our reliance on third parties for success in certain areas of Athenex’s business; our history of operating losses and need to raise additional capital to continue as a going concern; competition; intellectual property risks; risks relating to doing business in China; and the other risk factors set forth from time to time in our SEC filings, copies of which are available for free in the Investor Relations section of our website at http://ir.athenex.com/phoenix.zhtml?c=254495&p=irol-sec or upon request from our Investor Relations Department. All information provided in this release is as of the date hereof and we assume no obligation and do not intend to update these forward-looking statements, except as required by law.

CONTACTS

Investor Relations:

Tim McCarthy
Managing Director, LifeSci Advisors, LLC
Tel: +1 716-427-2952 
Direct: +1 212-915-2564

Athenex, Inc.:

Randoll Sze
Chief Financial Officer
Email: randollsze@athenex.com

Jacqueline Li
Corporate Development and Investor Relations
Email: jacquelineli@athenex.com

Primary Logo


[ Back To TMCnet.com's Homepage ]









Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2019 Technology Marketing Corporation. All rights reserved | Privacy Policy